Literature DB >> 19731362

IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression.

Mikiko Tohyama1, Yasushi Hanakawa, Yuji Shirakata, Xjuju Dai, Lujun Yang, Satoshi Hirakawa, Sho Tokumaru, Hidenori Okazaki, Koji Sayama, Koji Hashimoto.   

Abstract

IL-20 cytokine subfamily members, including IL-19, IL-20, and IL-24, are highly expressed in psoriatic skin lesions. Here, we demonstrate that psoriasis mediators IL-17 and IL-22 synergistically induce the production of IL-20 subfamily proteins in cultured human keratinocytes. Interestingly, expression of the IL-22 receptor (IL-22R) also increased in epidermal lesions versus normal skin. IL-22R over-expression using an adenoviral vector to mimic psoriatic conditions in cultured keratinocytes significantly enhanced IL-17- and IL-22-induced production of IL-20 subfamily cytokines. Furthermore, IL-17 and IL-22 coordinately enhanced MIP-3alpha, IL-8, and heparin-binding EGF-like growth factor (HB-EGF) production, depending on the amount of IL-22R expression. Additionally, because IL-20 and IL-24 share the IL-22R with IL-22, the function of IL-20 and IL-24 was also increased. IL-20 and IL-24 have effects similar to that of IL-22; IL-24 showed more potent expression than IL-20. A combination of IL-24 and IL-17 increased the production of MIP-3alpha, IL-8, and HB-EGF, as did a combination of IL-22 and IL-17. These data indicate that increased IL-22R expression in epidermal keratinocytes contributes to the pathogenesis of psoriasis through enhancing the coordinated effects of IL-22 and IL-17, inducing the production of the IL-20 subfamily, chemokines, and growth factors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19731362     DOI: 10.1002/eji.200939473

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  39 in total

1.  Interleukin-22: implications for liver ischemia-reperfusion injury.

Authors:  Paul J Chestovich; Yoichiro Uchida; William Chang; Mark Ajalat; Charles Lassman; Robert Sabat; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Transplantation       Date:  2012-03-15       Impact factor: 4.939

Review 2.  Janus-like effects of type I interferon in autoimmune diseases.

Authors:  Robert C Axtell; Chander Raman
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

3.  Amygdalin analogues inhibit IFN-γ signalling and reduce the inflammatory response in human epidermal keratinocytes.

Authors:  Iole Paoletti; Vincenza De Gregorio; Adone Baroni; Maria Antonietta Tufano; Giovanna Donnarumma; Juan Jesus Perez
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

4.  Role of oncostatin M in the pathogenesis of vernal keratoconjunctivitis: focus on tissue remodeling.

Authors:  Keitaro Mashimo; Ayumi Usui-Ouchi; Yousuke Ito; Rei Wakasa-Arai; Norihiko Yokoi; Satoshi Kawasaki; Akira Murakami; Akira Matsuda; Nobuyuki Ebihara
Journal:  Jpn J Ophthalmol       Date:  2021-01-06       Impact factor: 2.447

5.  Cytokine effects induced by the human autoallergen α-NAC.

Authors:  Susanne Hradetzky; Lennart M Roesner; Hari Balaji; Annice Heratizadeh; Irene Mittermann; Rudolf Valenta; Thomas Werfel
Journal:  J Invest Dermatol       Date:  2014-01-17       Impact factor: 8.551

Review 6.  Targeting IL-10 Family Cytokines for the Treatment of Human Diseases.

Authors:  Xiaoting Wang; Kit Wong; Wenjun Ouyang; Sascha Rutz
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-02-01       Impact factor: 10.005

Review 7.  Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease.

Authors:  Reiko M Onishi; Sarah L Gaffen
Journal:  Immunology       Date:  2010-03       Impact factor: 7.397

8.  Activation of the IL-6/JAK/STAT3 signaling pathway in human middle ear cholesteatoma epithelium.

Authors:  Wei Liu; Shumin Xie; Xing Chen; Xingwang Rao; Hongmiao Ren; Bing Hu; Tuanfang Yin; Yuyan Xiang; Jihao Ren
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

9.  Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis.

Authors:  Nora Koutruba; Jason Emer; Mark Lebwohl
Journal:  Ther Clin Risk Manag       Date:  2010-04-15       Impact factor: 2.423

10.  Decreased interleukin-20 level in patients with systemic sclerosis: are they related with angiogenesis?

Authors:  Erkan Aydoğdu; Ömer Nuri Pamuk; Salim Dönmez; Gülsüm Emel Pamuk
Journal:  Clin Rheumatol       Date:  2013-06-29       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.